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Pituitary adenomas are now described as pituitary neuroendocrine tumors (PitNets) [1]. A large proportion,
approximately 22–54%, is clinically defined as nonfunctioning pituitary adenomas and will present with signs
and symptoms of mass effect, rather than excessive hormone secretion. ‘Silent pituitary adenomas’ are tumors that
express one or more of the anterior pituitary hormones or their transcription factors, which can be visualized by
immunohistochemical analysis. Although, they do not secrete hormones at a clinically relevant level. Silent pituitary
adenomas can be further sub categorized into totally silent or clinically silent tumors [2].
A null cell adenoma that is restricted to a primary anterior pituitary tumor, is hormone negative (determined
by immunohistochemistry) and does not express any of the pituitary transcription factors. The clinical picture of
pituitary adenomas reflects a continuum between functional adenomas and ‘totally silent’ adenomas. The functional
status of the tumor can change throughout the disease course [3].
Somatotropic tumors are growth hormone (GH) producing tumors. These account for approximately 20% of
surgically treated pituitary tumors and more than 95% of cases of acromegaly. Very rare cases of acromegaly are due
to an excess of the GH-releasing hormone (GHRH). This may be associated with neuroendocrine tumors of lung,
pancreas, medullary thyroid cancer, pheochromocytomas and hypothalamic gangliocytomas. Ectopic production
of GH has been reported from rare cases of pancreatic neuroendocrine tumor or lymphoma [4,5].
Many familial syndromes have been reported to predispose to acromegaly or gigantism. These include multiple
MEN1 and MEN4, familial isolated pituitary adenoma and Carney complex. A sporadic germline mosaic disorder
McCune-Albright disease can also result in GH excess [6]. A rare genetic syndrome, X-linked acrogigantism has been
described in early-onset childhood gigantism [7]. In familial cases, onset is in young age with florid presentation
due to high GH levels. The response to medical treatment is poor [7].
Silent somatotroph adenomas lack clinical and biological signs of acromegaly but are GH-immunoreactive
tumors. They represent approximately 2–4% of all pituitary adenomas in surgical series. Patients with truly silent
somatotroph adenomas have normal preoperative GH and IGF-1 levels; some cases can be clinically silent but
demonstrate a lack of GH suppression and elevated IGF-1 levels (whispering adenomas) [8].
Growth hormone excess can be due to pure somatotroph adenomas and these can be densely granulated (DGSA)
or sparsely granulated (SGSA).
DGSA are present in 30–50% of acromegaly cases. The cells are eosinophilic and are strongly as well as diffusely
positive for GH and α-subunits. They resemble normal somatotrophes. DGSA is usually present in older patients
and are slow-growing lesions. Patients have typical features of acromegaly and high levels of GH and IGF-1 and
imaging demonstrates characteristic bone changes of acromegaly and is associated with low intensity tumors on
T2-weighted MRI scans. The disease shows an excellent response to somatostatin analogs (SSAs).
SGSA accounts for 15–35% of patients with acromegaly. The cells are lightly eosinophilic or chromophobic.
The tumors identified usually demonstrate focal or weak GH expression and no α-subunit expression. SGSAs have
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characteristic fibrous bodies. A variant of somatotroph tumors may have occasional fibrous bodies. This is classified
as an intermediate type but behaves like a DGSA.
SGSAs can be more aggressive and in most cases, the Ki67 proliferation index is greater than 3%. SGSA is more
common in patients of younger age, presenting with rapidly growing tumors, which are large at the time of diagnosis.
The clinical presentation is subtle and the tumor may be classified as a silent tumor. Silent somatotroph adenomas
are more frequently sparsely granulated. Compared to DSGA, the levels of GH and IGF-1 are not high. On MRI
scans, SGSAs have a characteristic T2 hyperintensity and are found to have frequent cavernous sinus invasion.
SGSAs are often resistant to treatment with SSAs. SGSA are also associated with recently recognized histological
variants of GH excess such as plurihormonal tumors. This group of tumors expresses multiple hormones. Every
tumor type has distinct pathophysiology, resulting in variations in clinical manifestations, imaging and responses
to therapies [9].
These include:
• Mammosomatotrophs, which are composed of single population of Pit-1 cells. These express GH and prolactin
and α-subunit, estrogen receptor-α (ERα). Their clinical and biological features are very similar to the DGSA.
However, prolactin levels are generally higher than 4000 mU/l and are more frequently diagnosed in young
patients who initially present with acromegaly and gigantism. High levels of GH/IGF-1 can lead to earlier
diagnosis even in patients with relatively small tumors. They respond to SSAs and to dopamine agonists.
• Mixed somatotroph–lactotroph tumors are composed of two different cell populations, somatotrophs and
lactotrophs. Either of the cell population can be densely or sparsely granulated with various combinations
occurring. These tumors are distinct from mammosomatotrophs, composed of a single monomorphous cell
population that expresses both hormones. The tumors express Pit1 in all tumor cells, but ERα is only expressed
in cells that also express prolactin. The clinical characteristics of mixed somatotroph–lactotroph tumors are
dependent on the composition and the relative proportions of the two cell types. The behavior of these tumors
is uncertain because of a lack of clear pathology and different patterns of histological subtypes. More recently,
research has suggested that mixed somatotroph–lactotroph tumors are more likely to invade into the surrounding
tissue and are difficult to treat with a low surgical cure rate. However, it has been suggested that this may be due
to the sparsely granulated somatotroph component in many of these tumors [10].
• Mature plurihormonal Pit1-Lineage tumors resemble mammosomatotroph tumors, however, these tumors can
synthesize GH, prolactin, thyroid stimulating hormone, as well as express the transcription factor GATA3. The
patients may also have hyperthyroidism and goiter.
• Acidophil stem cell tumors consist of a single immature cell type, which are precursors of GH and prolactin cells.
Upon histological analysis acidophil stem cell tumors demonstrate characteristic oncocyte with occasional fibrous
bodies. They mainly express prolactin and GH only focally. Mostly patients present with hyperprolactinemia
and acromegaly are less obvious as GH levels are mildly elevated. Acidophil stem cell tumors are more aggressive
than common prolactinomas. The prolactin levels are disproportionally low for the size of the tumor and are
frequently resistant to dopamine agonists treatment.
• Poorly differentiated Pit1-Lineage tumor is a neoplasm, which is composed of poorly differentiated, chromo-
phobic cells that express Pit-1, as well as focal estrogen receptor and GATA3. These tumors can produce different
combinations of GH, prolactin, α-subunit and/or thyroid stimulating hormone. Originally, this group was
described as silent tumors, but patients may manifest with acromegaly, hyperprolactinemia, and/or hyperthy-
roidism. The tumors are mostly macroadenomas, aggressive and invasive, with increased risk for recurrence
following surgery and lower rates of disease-free survival. Radiologic imaging frequently identifies cavernous
sinus invasion with clivus and suprasellar growth involvement. Such tumors have been reported in members of
MEN [10,11].
The diagnosis of pituitary hyperplasia is usually made on histology. It should result in the investigation of a
GHRH-secreting tumor. If a GHRH secreting tumor is not identified, then the possibility of an underlying genetic
syndrome, such as MEN1/MEN4, Carney Complex, McCune Albright and X-linked acrogigantism syndrome,
should be considered [12].
Currently available treatments for the GH-secreting tumors include surgery, medical therapy with SSAs,
dopamine agonists, and/or a GH receptor antagonist (Pegvisomant) and radiotherapy. The treatment results
in remission of disease in approximately half of the patients. Dopamine agonists are a possible treatment op-
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tion for acromegaly, this is due to mammosomatotroph tumors, mixed somatotroph–lactotroph tumors and pure
somatotroph tumors presenting dopamine receptors on their surface.
In conclusion, the clinical spectrum of acromegaly varies from florid to subtle features and the diagnosis may
be missed in some patients who are presumed to have clinically nonfunctioning pituitary tumors or no pituitary
disorder. The various histopathological tumors resulting in acromegaly provide an explanation for the different
clinical, biochemical and radiological characteristics of these patients and may provide valuable information to both
researchers and clinicians as to why there is such varied response rate to different therapeutic approaches [10].
The classification of the granular pattern on histological subtypes has clinical relevance because it can be used as
a predictor of somatoroph adenoma response to medical therapies.
There is a significant difference in the rate of remission between DGSA and SGSA. SGSAs have higher rates of
incomplete resection and reoperation. They also tend to be unresponsive to therapy, particularly to SSAs and can
be associated with disease persistence. DGSAs are reported to have a higher rate of remission in response to surgery
as well as to medical therapy with SSAs. There is no difference in response to Pegvisomant between DGSA and
SGSA. Most of the patients with SGSA normalize IGF-1 levels on Pegvisomant [13].
The reported response rate to stereotactic radiosurgery in patients with DGAS and SGSAS is similar, between
70 and 80%, within 4 years of therapy.
In somatotrope adenoma associated with genetic syndromes, treatment with SSAs are usually ineffective.
Dopamine agonists can control prolactin levels but have no effect on GH and IGF-1 levels. Pegvisomant can
be used with good results in patients with pituitary hyperplasia. Acromegaly, caused as a result of pituitary hy-
perplasia, either primary or due to ectopic GHRH, also has unique clinical and radiographic features, which may
result in an alternative therapeutic approach being required [10].
Pituitary adenoma diagnosis is variable. It mainly relies on pathologists, who use electron microscopy and
experimental antibodies. The research field is moving to improve the understanding of pituitary specific transcription
factors to compliment immunohistochemistry (IHC) analysis. Identifying silent PitNET is essential, because these
tumors could be treated with cabergoline or SSAs and these tumors are more prevalent than currently believed.
Molecular studies are more sensitive than IHC in detecting the silent variants. Exploiting the underlying biology of
pituitary adenoma, combined with IHC stains for transcription factors would, therefore, improve the classification
of PitNET subtype, develop algorithms for individualized treatment of the subtypes and predict the long-term
outcome of these tumors. Such framework will provide a more efficient, rational and clinically diagnostic approach.
Most diagnostic laboratories are not equipped for this comprehensive diagnostic approach, as yet.
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